EP0342675A2 — Novel quinolonecarboxylic acid derivatives
Assigned to Chugai Pharmaceutical Co Ltd · Expires 1989-11-23 · 36y expired
What this patent protects
Novel compounds of the present invention are represented by the general formula (I) wherein R₁ is hydrogen atom or amino, R₂ is fluorine atom or methoxy, R₃ is hydrogen atom or a lower alkyl having 1 to 3 carbon atoms, and n is 0 or 1. The compounds of the general formula …
USPTO Abstract
Novel compounds of the present invention are represented by the general formula (I) wherein R₁ is hydrogen atom or amino, R₂ is fluorine atom or methoxy, R₃ is hydrogen atom or a lower alkyl having 1 to 3 carbon atoms, and n is 0 or 1. The compounds of the general formula (1) exhibit higher antibacterial activity with fewer side-effects than known quinolone antibiotics such as ofloxacin and norfloxacin. Further, the compounds having the general formula (1) have reduced phototoxicity which normally accompanies 6,8-difluoroquinoline antibiotics.
Drugs covered by this patent
- Tradjenta (LINAGLIPTIN) · Boehringer Ingelheim
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.